MCID: RTN022
MIFTS: 53

Retinal Vein Occlusion

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Retinal Vein Occlusion

MalaCards integrated aliases for Retinal Vein Occlusion:

Name: Retinal Vein Occlusion 37 12 51 41 14 69
Occlusion, of Retinal Vein 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1727
MeSH 41 D012170
NCIt 46 C34981
SNOMED-CT 64 46085004
UMLS 69 C0035328

Summaries for Retinal Vein Occlusion

MalaCards based summary : Retinal Vein Occlusion, also known as occlusion, of retinal vein, is related to central retinal vein occlusion and macular retinal edema. An important gene associated with Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 central retinal vein occlusion 31.6 APOH F2 F5 IL6 LOXL1 MTHFR
2 macular retinal edema 31.6 IL6 SERPINF1 VEGFA
3 purpura 30.3 APOH F2 SERPINC1
4 branch retinal artery occlusion 30.3 APOH F2 MTHFR SERPINC1
5 factor xii deficiency 30.2 APOH F5 SERPINC1
6 thrombocytosis 30.1 F2 IL6 SERPINC1
7 retinal vasculitis 30.1 APOH CCL2
8 macular holes 30.1 CCL2 SERPINF1 VEGFA
9 microvascular complications of diabetes 5 30.0 SERPINE1 SERPINF1 VEGFA
10 nonarteritic anterior ischemic optic neuropathy 30.0 F2 F5 MTHFR SERPINC1
11 ischemic optic neuropathy 30.0 APOH F2 F5 MTHFR SERPINC1
12 protein s deficiency 29.9 APOH F2 F5 MTHFR SERPINC1
13 retinal vascular disease 29.8 MTHFR SERPINF1 VEGFA
14 protein c deficiency 29.8 F2 F5 MTHFR SERPINC1
15 retinal artery occlusion 29.8 APOH F2 F5 MTHFR SERPINC1 SERPINE1
16 eclampsia 29.7 F2 F5 MTHFR SERPINC1
17 coronary artery anomaly 29.7 IL6 MTHFR SERPINE1
18 sneddon syndrome 29.7 APOH F2 F5 SERPINC1
19 pulmonary hypertension 29.6 IL6 SERPINC1 SERPINE1 VEGFA
20 antithrombin iii deficiency 29.6 APOH F2 F5 MTHFR SERPINC1
21 antiphospholipid syndrome 29.6 APOH F2 F5 MTHFR SERPINC1
22 diabetic macular edema 29.6 CCL2 IL6 SERPINF1 VEGFA
23 temporal arteritis 29.5 APOH CCL2 IL6
24 thrombophilia 29.5 APOH F2 F5 MTHFR SERPINC1 SERPINE1
25 thrombosis 29.3 APOH F2 F5 MTHFR SERPINC1 SERPINE1
26 cerebrovascular disease 29.3 F2 F5 IL6 MTHFR SERPINE1
27 thrombophilia due to thrombin defect 29.1 APOH F2 F5 MTHFR SERPINC1 SERPINE1
28 retinal vascular occlusion 28.7 APOH CCL2 F2 F5 MTHFR SERPINC1
29 hellp syndrome 28.5 APOH F2 F5 IL6 MTHFR SERPINC1
30 vascular disease 28.4 APOH CCL2 F5 MTHFR SERPINC1 SERPINE1
31 arteries, anomalies of 28.2 CCL2 F2 IL6 MTHFR SERPINC1 SERPINE1
32 pre-eclampsia 28.2 APOH F2 F5 IL6 MTHFR SERPINC1
33 myocardial infarction 27.9 CCL2 F2 F5 IL6 ITGA2 MTHFR
34 partial of retinal vein occlusion 12.2
35 retinitis 11.3
36 hydrops, lactic acidosis, and sideroblastic anemia 11.0
37 endotheliitis 10.5
38 paracetamol poisoning 10.5 F2 F5
39 hemifacial spasm 10.5 MTHFR VEGFA
40 may-thurner syndrome 10.5 APOH F5
41 mesenteric vascular occlusion 10.5 F2 MTHFR
42 osteoporotic fracture 10.5 IL6 MTHFR
43 acanthamoeba keratitis 10.5 APOH F5
44 critical limb ischemia 10.4 IL6 VEGFA
45 hemoglobin e disease 10.4 F2 F5
46 ischemic neuropathy 10.4 F2 MTHFR
47 intestinal impaction 10.4 F2 SERPINC1
48 fournier gangrene 10.4 F2 SERPINC1
49 leech infestation 10.4 F2 SERPINC1
50 alpha-2-plasmin inhibitor deficiency 10.4 F2 SERPINC1

Graphical network of the top 20 diseases related to Retinal Vein Occlusion:



Diseases related to Retinal Vein Occlusion

Symptoms & Phenotypes for Retinal Vein Occlusion

MGI Mouse Phenotypes related to Retinal Vein Occlusion:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ITGA2 LOXL1 MTHFR SERPINC1 APOH F2
2 cardiovascular system MP:0005385 9.97 LOXL1 SERPINC1 F2 SERPINE1 SERPINF1 F5
3 integument MP:0010771 9.76 ITGA2 LOXL1 MTHFR F2 SERPINE1 F5
4 nervous system MP:0003631 9.61 LOXL1 MTHFR SERPINC1 F2 SERPINF1 F5
5 reproductive system MP:0005389 9.17 LOXL1 MTHFR SERPINC1 F2 SERPINF1 VEGFA

Drugs & Therapeutics for Retinal Vein Occlusion

Drugs for Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
7
Lactitol Investigational Phase 4 585-86-4 3871
8 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
9 Mitogens Phase 4,Phase 3,Phase 1,Phase 2
10 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
13 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
15 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
16 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
17 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
18 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
19 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
21 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
25
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1
28 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1
29 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2
31 Fibrinolytic Agents Phase 4,Phase 3,Phase 1
32 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
33 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
35 Dexamethasone 21-phosphate Phase 4
36 Mitomycins Phase 4
37 Anticoagulants Phase 4,Phase 3
38 Glucuronyl glucosamine glycan sulfate Phase 4
39 Hypoglycemic Agents Phase 4
40 Dermatologic Agents Phase 4,Phase 1,Phase 2
41 Photosensitizing Agents Phase 4
42 histidine Nutraceutical Phase 4
43
Eplerenone Approved Phase 2, Phase 3 107724-20-9 443872 150310
44
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
45
Povidone-iodine Approved Phase 3 25655-41-8
46
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
47
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
48
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
50
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028

Interventional clinical trials:

(show top 50) (show all 214)

# Name Status NCT ID Phase Drugs
1 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
2 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
3 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
6 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
7 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
8 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4 ranibizumab
9 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
10 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4 Avastin;Osurdex;Avastin
11 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
12 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
13 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4 dexamethasone intravitreal implant
14 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
15 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
16 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
17 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
18 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
19 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
20 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
21 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
22 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4 Ranibizumab
23 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
24 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Recruiting NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
25 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Recruiting NCT02953938 Phase 4
26 Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium Recruiting NCT01573572 Phase 4 pegaptanib sodium injection
27 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
28 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4 Ranibizumab
29 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Active, not recruiting NCT02274259 Phase 4 Aflibercept;Ranibizumab
30 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4 Aflibercept
31 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion Not yet recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
32 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
33 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
34 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Unknown status NCT01635803 Phase 2, Phase 3 Bevacizumab;Ranibizumab
35 Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) Unknown status NCT01189526 Phase 3 Ranibizumab
36 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
37 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
38 Effect of Avastin in Juxtafoveal Telangiectasias Unknown status NCT00406380 Phase 3 Bevacizumab
39 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed NCT01599650 Phase 3 Ranibizumab
40 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
41 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3 dexamethasone implant
42 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3 ranibizumab
43 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
44 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
45 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
46 Combined Triple Procedure in Retinal Vein Occlusion (RVO) Completed NCT00805064 Phase 3 triamcinolone and bevacizumab
47 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3 ranibizumab
48 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
49 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
50 Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Completed NCT01512901 Phase 2, Phase 3 Betamethasone Microsphere (DE-102) Low Dose;Betamethasone Microsphere (DE-102) High Dose;Sham

Search NIH Clinical Center for Retinal Vein Occlusion

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Vein Occlusion cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Vein Occlusion:
Bone marrow-derived hematopoietic stem cells for retinopathy
Embryonic/Adult Cultured Cells Related to Retinal Vein Occlusion:
Bone marrow-derived hematopoietic CD34+ progenitors PMIDs: 22247454
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22247454

Cochrane evidence based reviews: retinal vein occlusion

Genetic Tests for Retinal Vein Occlusion

Anatomical Context for Retinal Vein Occlusion

MalaCards organs/tissues related to Retinal Vein Occlusion:

38
Eye, Endothelial, Retina, Bone, Myeloid, Monocytes, Testes

Publications for Retinal Vein Occlusion

Articles related to Retinal Vein Occlusion:

(show top 50) (show all 1204)
# Title Authors Year
1
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
2
Effects of Dexamethasone Implant on Multifocal Electroretinography in Central Retinal Vein Occlusion. ( 29403585 )
2018
3
YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey. ( 29364731 )
2018
4
Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. ( 29447089 )
2018
5
Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. ( 29399708 )
2018
6
Incidence of retinal vein occlusion in open-angle glaucoma: a nationwide, population-based study using the Korean Health Insurance Review and Assessment Database. ( 29360215 )
2018
7
Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion. ( 29376223 )
2018
8
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. ( 29426292 )
2018
9
Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure. ( 29399095 )
2018
10
Impact of Early Anatomical and Functional Responses to Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. ( 29393235 )
2018
11
Correlation between ischemic index of retinal vein occlusion and oxygen saturation in retinal vessels. ( 29366614 )
2018
12
Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. ( 29185099 )
2018
13
Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes. ( 29339919 )
2018
14
Risk of Retinal Vein Occlusion in Patients With End-Stage Renal Disease: A 12-Year, Retrospective, Nationwide Cohort Study in South Korea. ( 29302692 )
2018
15
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion. ( 28591282 )
2017
16
Central Retinal Vein Occlusion in 2 Patients Using Antipsychotic Drugs. ( 28924438 )
2017
17
Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. ( 28807635 )
2017
18
"Dye front reciprocation" in combined central retinal vein occlusion with cilioretinal artery infarction. ( 29133654 )
2017
19
Cilioretinal Artery Occlusion Combined with Central Retinal Vein Occlusion: What Is the Best Imaging Modality for the Follow-Up? ( 29430314 )
2017
20
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. ( 28492910 )
2017
21
Comments on 'Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA'. ( 28840855 )
2017
22
Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. ( 29274022 )
2017
23
Alternative ways to optimize treatment for retinal vein occlusion with peripheral capillary non-perfusion: a pilot study. ( 28954021 )
2017
24
Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion. ( 28922697 )
2017
25
Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform. ( 28811936 )
2017
26
Retinal Vein Occlusion Review. ( 29280368 )
2017
27
Oxidant-Antioxidant Balance in the Aqueous Humor of Patients with Retinal Vein Occlusion. ( 29278975 )
2017
28
Association of retinal vein occlusion, homocysteine, and the thrombophilic mutations in a Turkish population: A case-control study. ( 28085519 )
2017
29
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. ( 28085526 )
2017
30
Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature. ( 28603574 )
2017
31
Branch retinal vein occlusion: the importance of the topographical distribution of retinal vessels among risk factors. ( 28085135 )
2017
32
Central retinal vein occlusion after coronary artery bypass surgery: A case report. ( 28605930 )
2017
33
Management of macular edema due to central retinal vein occlusion - The role of aflibercept. ( 29018760 )
2017
34
En Face Optical Coherence Tomography Analysis to Assess the Spectrum of Perivenular Ischemia and Paracentral Acute Middle Maculopathy in Retinal Vein Occlusion. ( 28802731 )
2017
35
Metamorphopsia associated with central retinal vein occlusion. ( 29049410 )
2017
36
Morphologic and Functional Retinal Vessel Changes in Branch Retinal Vein Occlusion: AnA Optical Coherence Tomography Angiography Study. ( 28837791 )
2017
37
Health care claims for primary open-angle glaucoma and retinal vein occlusion from an 11-year nationwide dataset. ( 28808282 )
2017
38
Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion. ( 28739419 )
2017
39
Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. ( 28946138 )
2017
40
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. ( 28620704 )
2017
41
Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. ( 28447244 )
2017
42
CONN SYNDROME PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION. ( 28644176 )
2017
43
Predictive Value of Baseline Biochemical Parameters for Clinical Response of Macular Edema to Bevacizumab in Eyes With Central Retinal Vein Occlusion: A Retrospective Analysis. ( 29082677 )
2017
44
EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. ( 28767552 )
2017
45
Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series. ( 28031700 )
2017
46
Robot-assisted retinal vein cannulation in an inA vivo porcine retinal vein occlusion model. ( 28084059 )
2017
47
Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial. ( 28979743 )
2017
48
High Altitude Retinopathy Presenting as Central Retinal Vein Occlusion in a Soldier. ( 29185408 )
2017
49
RETINAL MICROVASCULATURE AND VISUAL ACUITY AFTER INTRAVITREAL AFLIBERCEPT IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. ( 28902097 )
2017
50
Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa. ( 28828184 )
2017

Variations for Retinal Vein Occlusion

Expression for Retinal Vein Occlusion

Search GEO for disease gene expression data for Retinal Vein Occlusion.

Pathways for Retinal Vein Occlusion

GO Terms for Retinal Vein Occlusion

Cellular components related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 APOH CCL2 F2 F5 IL6 LOXL1
2 extracellular matrix GO:0031012 9.62 APOH LOXL1 SERPINE1 SERPINF1
3 endoplasmic reticulum lumen GO:0005788 9.56 F2 F5 IL6 SERPINC1
4 platelet alpha granule lumen GO:0031093 9.33 F5 SERPINE1 VEGFA
5 extracellular space GO:0005615 9.32 APOH CCL2 F2 F5 IL6 LOXL1

Biological processes related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.77 CCL2 F2 IL6 SERPINE1 VEGFA
2 cellular protein metabolic process GO:0044267 9.76 F2 F5 IL6 SERPINC1
3 regulation of cell shape GO:0008360 9.74 CCL2 F2 VEGFA
4 negative regulation of endopeptidase activity GO:0010951 9.72 SERPINC1 SERPINE1 SERPINF1
5 cellular response to lipopolysaccharide GO:0071222 9.71 CCL2 IL6 SERPINE1
6 platelet degranulation GO:0002576 9.62 APOH F5 SERPINE1 VEGFA
7 hemostasis GO:0007599 9.61 F2 F5 SERPINC1
8 positive regulation of collagen biosynthetic process GO:0032967 9.59 F2 ITGA2
9 negative regulation of endothelial cell migration GO:0010596 9.58 APOH SERPINF1
10 fibrinolysis GO:0042730 9.58 F2 SERPINE1
11 blood coagulation, intrinsic pathway GO:0007597 9.56 APOH F2
12 negative regulation of blood coagulation GO:0030195 9.52 APOH SERPINE1
13 positive regulation of leukocyte migration GO:0002687 9.51 ITGA2 VEGFA
14 positive regulation of positive chemotaxis GO:0050927 9.49 ITGA2 VEGFA
15 peptidyl-glutamic acid carboxylation GO:0017187 9.48 F2 VKORC1
16 regulation of blood coagulation GO:0030193 9.43 APOH F2 SERPINC1
17 positive regulation of STAT protein import into nucleus GO:2000366 9.4 F2 IL6
18 blood coagulation GO:0007596 9.35 F2 F5 ITGA2 SERPINC1 VKORC1
19 positive regulation of blood coagulation GO:0030194 9.33 APOH F2 SERPINE1
20 negative regulation of fibrinolysis GO:0051918 8.8 APOH F2 SERPINE1

Molecular functions related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 F2 IL6 VEGFA
2 serine-type endopeptidase inhibitor activity GO:0004867 9.13 SERPINC1 SERPINE1 SERPINF1
3 heparin binding GO:0008201 8.92 APOH F2 SERPINC1 VEGFA

Sources for Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....